Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorCarl Frasch
Life of this patent
Estimating the term…
Abstract
The present invention discloses a vaccine against Neisseria meningitidis Group B, serotype 2b strain. More particularly, the present invention is related to an aluminum hydroxide adjuvanted vaccine containing only a single serotype 2 antigen being protective against both 2a and 2b meningococcal disease.
Claims8
A vaccine comprising a single group B, serotype 2b lipopolysaccharide depleted outer membrane antigen from a Neisseria meningitidis group B, serotype 2b strain, said vaccine having aluminum containing adjuvant and capable of inducing in a host protective antibodies against both Neisseria meningitidis group B, serotype 2a and 2b invasive disease.
A method of protecting a host against Neisseria meningitidis group B, serotype 2a and 2b invasive disease, comprising administering to said host a vaccine comprising a single group B, serotype 2b lipopolysachharide depleted outer membrane antigen from a Neisseria meningitidis group B, serotype 2b strain, said vaccine having aluminum containing adjuvant and capable of inducing in a host protective antibodies against both Neisseria meningitidis group B, serotype 2a and 2b invasive disease.
Dependencies are inferred from the claim text.